For education only · Not medical advice
← All articles
September 2026 Longevity & Anti-Aging 7 min read

MOTS-c peptide: the human trial belonged to a different molecule

MOTS-c is one of the most interesting molecules in longevity biology and one of the most badly described, because the single substantial human dataset attached to its name was generated by a chemically modified analogue called CB4211, not by MOTS-c itself.

The short answer

  • MOTS-c is a 16-amino-acid peptide encoded inside your own mitochondrial DNA, in the 12S rRNA gene. That part is real and remarkable.
  • Its evidence tier for every use it is sold for, metabolic, performance, longevity and bone, is Preclinical only. There is no completed human efficacy trial of native MOTS-c of any kind.
  • The human trial people cite belongs to CB4211, a modified analogue from a different developer. That programme reached Early human data (phase 1a/1b, 88 participants total).
  • A phase 2a trial of MOTS-c itself started on 2 February 2026 with estimated primary completion in February 2027. As of September 2026 there are no results.
  • MOTS-c is prohibited at all times by WADA and is detectable in plasma by a validated method.

What MOTS-c actually is

Mitochondria carry their own small circular genome, about 16.6 kb, which encodes 13 respiratory-chain subunits, 22 tRNAs and 2 rRNAs. In 2015 a group at USC reported that a short open reading frame tucked inside the 12S rRNA gene (MT-RNR1) also encodes a peptide: 16 amino acids, roughly 2.1 kDa, which they named MOTS-c. A second mitochondrial-derived peptide, humanin, sits in the neighbouring MT-RNR2 gene.

The biology that follows is the reason this molecule has a fan base. In cells and rodents, MOTS-c inhibits the folate cycle and the purine synthesis tethered to it, which causes the AMPK-activating intermediate AICAR to accumulate and switches on AMPK, the cell’s low-energy sensor (Lee 2015). Under metabolic stress it also translocates out of the mitochondrion and into the nucleus, where it binds antioxidant response element regions and interacts with NRF2 and other stress-responsive transcription factors (Kim 2018). A peptide written in mitochondrial DNA that goes and regulates the nuclear genome is a genuinely new kind of signalling, and it deserves the attention it gets.

None of that is the same claim as “injecting it does something in a person.”

The category error at the centre of the marketing

Search for the MOTS-c peptide and you will find it described as having early human data, usually with two specifics attached: that a trial tested single subcutaneous doses “up to about 10 mg”, and that a small 2021 randomized trial used a weight-based intravenous dose. Both of those specifics are wrong, and the tier is wrong too.

Here is what the primary records show.

The tier. Native MOTS-c has no completed human interventional study. The trial that exists, NCT03998514, tested CB4211, an analogue whose exact sequence modifications were never published in the peer-reviewed literature. Crediting MOTS-c with its analogue’s trial is the same mistake as crediting TB-500 with the trials of full-length thymosin beta-4. Different molecule, different formulation, different stability.

The dose figure. The CB4211 phase 1a used single and 7-day multiple ascending subcutaneous doses of 0.2 to 3.0 mg/kg/day in 65 healthy adults. The phase 1b used 25 mg subcutaneously once daily for four weeks. The “up to about 10 mg” figure appears in neither the 2021 conference poster nor the trial registry record.

The intravenous RCT. It could not be located. No randomized trial of MOTS-c or CB4211 using weight-based intravenous dosing appears in PubMed or ClinicalTrials.gov, and FDA’s own July 2026 literature review states that it identified no clinical studies or human exposure data for MOTS-c by any route. The likeliest explanation is confusion with the CB4211 weight-based subcutaneous cohorts. Treat that claim as unverified and probably erroneous.

What the CB4211 trial actually found

The phase 1b is worth reading carefully, because it is a small masterclass in why uncontrolled clinic observations mislead.

Twenty-three obese participants with non-alcoholic fatty liver disease were randomized, 11 on drug and 9 on placebo in the analysis, and kept inpatient on a standardized diet for four weeks on 25 mg subcutaneously daily. Liver enzymes moved: ALT fell 21% on drug versus a 4% rise on placebo, AST fell 28% versus 11%, and fasting glucose fell 6% versus no change, all reported as statistically significant versus placebo. Body weight showed a trend only.

Liver fat, the endpoint the molecule was being developed for, fell by almost exactly the same amount in both arms: 5.03% on drug and 4.88% on placebo. The investigators attributed that to the controlled inpatient diet. In other words, the diet produced a large, real, measurable change that a clinic without a placebo arm would have booked as drug efficacy.

Safety over those four weeks was unremarkable: no serious adverse events, and mild to moderate injection-site reactions as the only treatment-related event above 10%.

The gaps regulators have put in writing

FDA’s July 2026 briefing document on MOTS-c is unusually blunt for a molecule with this much promotion behind it. It concluded that the molecular target or targets through which MOTS-c acts remain unknown, that no dose-response relationship has been established in vivo, and that it is therefore not possible to predict which organs an exogenous dose would reach or affect. No human pharmacokinetic data were identified by the agency or by the nominator. No in vivo animal pharmacokinetic profile was identified either.

There is also a stability problem. In human whole blood in vitro, MOTS-c is rapidly hydrolysed into N-terminally truncated fragments (Knoop 2019). Whether a subcutaneous dose can sustain an active concentration at all is an open question, not a solved one.

On the regulatory map, as of September 2026: MOTS-c is not an approved drug anywhere. It was formerly in FDA’s 503A category 2, and FDA’s safety-risk page (content current as of 22 April 2026) now lists it under “nominated but withdrawn”, which leaves it in no category and does not make it lawful to compound. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5 with 2 abstentions to recommend adding MOTS-c to the 503A bulks list for obesity and osteoporosis, against FDA scientists’ own written recommendation. The vote is advisory; the rulemaking required to act on it had not occurred as of September 2026. In Canada there is no DIN and no market authorization, and MOTS-c is named explicitly in the Health Canada public advisory of 9 April 2026 on unauthorized injectable peptides. A “research use only” label does not change any of that.

For athletes, MOTS-c is named by name in the 2026 WADA Prohibited List under S4.4.1, activators of AMPK, alongside AICAR and BAM15. Prohibited at all times, and detectable: the validated plasma LC-MS method reaches 100 pg/mL.

The human MOTS-c literature you can trust

There is a real and growing human literature on MOTS-c. Almost all of it measures the peptide rather than administering it. Circulating MOTS-c is detectable, rises acutely with exercise, and differs across metabolic states. Serum levels correlated with lower-body strength but not with VO2max in one study (Domin 2023). A meta-analysis of mitochondrial-derived peptides and metabolic states found the pooled picture hard to interpret partly because ELISA values vary so much between assays (Zhou 2024).

The genetics are the most interesting human piece. An Asian-specific mitochondrial variant, m.1382A>C, produces a K14Q substitution in MOTS-c. In a meta-analysis of three Japanese and Singaporean cohorts totalling 27,527 people, men carrying the C allele had a higher prevalence of type 2 diabetes, concentrated in the least physically active tertile, and K14Q-MOTS-c was less insulin-sensitising in cells and did not reproduce wild-type effects in mice (Zempo 2021).

That is good evidence about the endogenous peptide. It says nothing about what an injection does. The one question worth asking of any human MOTS-c paper is: was the peptide administered, or measured?

Two more things cut against the longevity framing specifically. Mitochondrial-derived peptides have been reported to exacerbate senescence in some contexts (Mendelsohn 2018), and the cancer biology is bidirectional, with MOTS-c suppressing progression in one ovarian model while related peptides promote it in others. And because MOTS-c is an endogenous human peptide, antibodies raised against an injected preparation could in principle cross-react with your own. That is a more serious class of risk than for a fully synthetic non-human sequence, not a lesser one.

For the problems people buy MOTS-c to address, see how peptides work in the body and the metabolic health foundation piece for what has actual human outcome data behind it. The molecule page is at /peptides/mots-c/.

The bottom line

MOTS-c is a real discovery being sold as though the discovery were a therapy. The mouse work is interesting, the human genetics are interesting, and the one substantial human trial was run on a different molecule and did not separate from placebo on its main endpoint. The thing to wait for is the phase 2a readout estimated for February 2027, not the rodent literature.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Peptides 101MitochondriaEvidence Tiers
For education only · Not medical advice